Our latest news

Kenzelmann A, Boch C, Schmidt R, Richter M, Schulz M. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024 Dec 9;12(12):2794. doi: 10.3390/biomedicines12122794. PMID: 39767701; PMCID: PMC11673003. Abstract Background/objectives: Neurodegenerative diseases are a major cause of morbidity and mortality worldwide, and their public health burden continues to increase. There is […]

Würth, R., Donato, E., Michel, L.L. et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling. Nat Cancer (2025). https://doi.org/10.1038/s43018-024-00882-2 Abstract Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively […]

Leppä, AM., Grimes, K., Jeong, H. et al. Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype. Nat Genet 56, 2790–2803 (2024). https://doi.org/10.1038/s41588-024-01999-x Abstract Chromosomal instability is a major driver of intratumoral heterogeneity (ITH), promoting tumor progression. In the present study, we combined structural variant discovery and nucleosome occupancy profiling with […]

Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation / exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing efficacy and safety of bemdaneprocel in people living with moderate Parkinson’s disease / Expected to be initiated in H1 2025, exPDite-2 is […]

Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new […]

EMBL researchers showed for the first time that adding a sugar to proteins inside cells is crucial for embryo development and for shutting down completely harmful parts of the genome in vivo Protein modifications are key to cell survival because they ensure they do what they are supposed to do in a healthy system. One […]

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Previously, in Cohort 6, dose […]

Non-viral platform for efficient drug transfer to facilitate clinical developments Heidelberg, 15.01.2025 – PROGEN, leading manufacturer of Adeno-Associated-Virus (AAV) analytical tools for gene therapy research and development, announces the launch of LNPs for the versatile delivery of therapeutic agents into cells. In the past decade, PROGEN has driven progress in gene therapy by providing reliable […]

EMBL and ELLIS deepen relationship to drive artificial intelligence (AI) in European life science research, training, and technology A new collaborative agreement aims to help position Europe at the forefront of AI-driven advancements in life sciences research. The European Molecular Biology Laboratory (EMBL) and the European Laboratory for Learning and Intelligent Systems (ELLIS) have agreed […]